•
Enables rapid time to treatment: After a sample is obtained and placed into the device, results should be available to users within approximately 30 minutes.
•
High performance: Tests should be proven to achieve at least 95% accuracy, enabling greater confidence in the results and less-frequent testing.
The lightning-quick development and rollout of the COVID-19 vaccine has been among humanity’s greatest scientific achievements in recent decades, but we can’t allow this accomplishment to distract us from one next critical step in managing the pandemic: the development of rapid, accessible and accurate COVID-19 at home tests. The virus isn’t going anywhere, particularly from a global perspective, and the investments we make to improve rapid-testing technology today will pay future dividends in the form of saved lives and higher-performing economies.
About the author: Ron Chiarello is founder, CEO and chairman of the board of Alveo Technologies. Alveo is leading the transformation of the consumer health tech market with a low-cost, easy-to-use diagnostic platform that will change the way infectious diseases are detected and managed. With an initial focus on acute respiratory infections, including COVID-19, Influenza A/B and RSV, Alveo’s agile and dynamic be.well diagnostic platform can be adapted to detect a wide range of diseases that threaten public health.
Back to HCB News
